Segment 3 - The CoMMpass Study
Ms Young addresses MMRF's CoMMpass study, a longitudinal study that is following 1000 patients who have been newly diagnosed with multiple myeloma, from initial diagnosis over a period of at least 5 years.
Ms Young addresses MMRF’s CoMMpass study, a longitudinal study that is following 1000 patients who have been newly diagnosed with multiple myeloma, from initial diagnosis over a period of at least 5 years. MMRF hopes the CoMMpass study will help researchers and providers better understand the natural history of the disease and “give clues” in terms of how best to treat patients using precision medicine approaches.
Dr Goldberg cautions that getting any early diagnosis can sometimes be problematic in determining whether a patient should start treatment. He also comments on existing and emerging agents for treatment of multiple myeloma.
